Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

@article{Armstrong2010ProphylaxisOC,
  title={Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.},
  author={E. Armstrong},
  journal={Journal of managed care pharmacy : JMCP},
  year={2010},
  volume={16 3},
  pages={
          217-30
        }
}
  • E. Armstrong
  • Published 2010
  • Medicine
  • Journal of managed care pharmacy : JMCP
BACKGROUND Vaccines have demonstrated cost-effectiveness in managed care through the prevention of disease. As new vaccines for previously untargeted conditions are developed, pharmacoeconomic modeling is becoming even more critical for the quantification of value in the health care industry. Two recently developed vaccines aimed at prevention of infection from human papillomavirus (HPV) types 16 and 18 have proven to be highly efficacious. HPV 16 and 18 are the 2 most common oncogenic strains… Expand
Human papilloma virus vaccine for low and middle income countries: A step too soon?
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers
Human Papillomavirus Infection and Vaccination.
Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK
HPV Vaccination in India: Critical Appraisal
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Health and economic implications of HPV vaccination in the United States.
Age-based programs for vaccination against HPV.
A Multi-Type HPV Transmission Model
...
1
2
3
4
5
...